4.56
Ardelyx Inc stock is traded at $4.56, with a volume of 4.42M.
It is down -5.30% in the last 24 hours and down -11.11% over the past month.
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. It product Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.
See More
Previous Close:
$4.815
Open:
$4.75
24h Volume:
4.42M
Relative Volume:
1.04
Market Cap:
$1.09B
Revenue:
$251.85M
Net Income/Loss:
$-72.58M
P/E Ratio:
-14.55
EPS:
-0.3134
Net Cash Flow:
$-63.80M
1W Performance:
-0.22%
1M Performance:
-11.11%
6M Performance:
-22.45%
1Y Performance:
-29.63%
Ardelyx Inc Stock (ARDX) Company Profile
Name
Ardelyx Inc
Sector
Industry
Phone
510-745-7047
Address
34175 ARDENWOOD BLVD., FREMONT, CA
Compare ARDX with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
ARDX
Ardelyx Inc
|
4.56 | 1.09B | 251.85M | -72.58M | -63.80M | -0.3134 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
477.52 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
561.49 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
595.70 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
232.75 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
229.22 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Ardelyx Inc Stock (ARDX) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Mar-07-25 | Resumed | Ladenburg Thalmann | Buy |
Mar-04-25 | Initiated | BTIG Research | Buy |
Nov-11-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
Jul-02-24 | Downgrade | Piper Sandler | Overweight → Neutral |
Apr-05-24 | Initiated | Leerink Partners | Outperform |
Dec-18-23 | Initiated | Raymond James | Strong Buy |
Sep-07-23 | Initiated | H.C. Wainwright | Buy |
Aug-25-23 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
Mar-03-23 | Upgrade | Wedbush | Neutral → Outperform |
Nov-17-22 | Upgrade | Piper Sandler | Neutral → Overweight |
May-06-22 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
Dec-01-21 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
Oct-14-21 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
Jul-21-21 | Downgrade | Jefferies | Buy → Hold |
Jul-20-21 | Downgrade | Piper Sandler | Overweight → Neutral |
Jul-20-21 | Downgrade | Wedbush | Outperform → Neutral |
Mar-23-21 | Initiated | Wedbush | Outperform |
Jan-06-21 | Initiated | Cantor Fitzgerald | Overweight |
Oct-20-20 | Resumed | Citigroup | Buy |
Feb-18-20 | Resumed | Jefferies | Buy |
Feb-12-20 | Initiated | Citigroup | Buy |
Feb-10-20 | Initiated | Cowen | Outperform |
Apr-08-19 | Initiated | Piper Jaffray | Overweight |
Aug-24-18 | Initiated | Jefferies | Buy |
Mar-19-18 | Resumed | Leerink Partners | Outperform |
Nov-29-17 | Reiterated | Citigroup | Buy |
Nov-22-17 | Reiterated | Ladenburg Thalmann | Buy |
Oct-17-17 | Resumed | Leerink Partners | Outperform |
Mar-31-16 | Initiated | Ladenburg Thalmann | Buy |
Mar-09-16 | Initiated | Cantor Fitzgerald | Buy |
Mar-03-16 | Initiated | Citigroup | Buy |
View All
Ardelyx Inc Stock (ARDX) Latest News
Press Release Distribution & PR Platform - ACCESS Newswire
Lobbying Update: $620,000 of ARDELYX INC. lobbying was just disclosed - Nasdaq
Ardelyx to Report First Quarter 2025 Financial Results on May 1, 2025 - The Manila Times
Ardelyx to Report First Quarter 2025 Financial Results on May 1, 2025 | ARDX Stock News - GuruFocus
Ardelyx, Inc. Schedules Conference Call to Discuss Q1 2025 Financial Results and Business Update - Nasdaq
Is Ardelyx Inc. (NASDAQ:ARDX) the Best Biotech Penny Stock to Buy According to Hedge Funds? - Insider Monkey
April 2025's Top Penny Stocks To Watch - Yahoo Finance
13 Best Biotech Penny Stocks to Buy According to Hedge Funds - Insider Monkey
Stride Announces Date for Third Quarter Fiscal Year 2025 Earnings Call - The Globe and Mail
Ardelyx reveals new findings on CKD treatment XPHOZAH at NKF event - Investing.com Canada
Ardelyx reveals new findings on CKD treatment XPHOZAH at NKF event By Investing.com - Investing.com South Africa
Post-Hoc Analysis of the OPTIMIZE Study Supporting XPHOZAH® (tenapanor) to be Presented at the National Kidney Foundation Spring Clinical Meetings - The Manila Times
Ontario Teachers' Appoints Terry Hickey as Chief Technology Officer - The Globe and Mail
Class Action Filed Against Ardelyx, Inc. (ARDX) Seeking Recovery for InvestorsContact Levi & Korsinsky - ACCESS Newswire
ARDX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Ardelyx, Inc. Investors Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Ardelyx CEO Michael Raab sells $191k in stock - Investing.com
Ardelyx CEO Michael Raab sells $191k in stock By Investing.com - Investing.com UK
Ardelyx stock hits 52-week low at $4.29 amid challenges By Investing.com - Investing.com South Africa
Ardelyx stock hits 52-week low at $4.29 amid challenges - Investing.com Australia
How To Trade (ARDX) - news.stocktradersdaily.com
Levi's (LEVI) Reports Q1: Everything You Need To Know Ahead Of Earnings - The Globe and Mail
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of October 15, 2024 in Ardelyx, Inc. LawsuitARDX - ACCESS Newswire
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of October 15, 2024 in Ardelyx LawsuitARDX - ACCESS Newswire
Ardelyx to Share a Post-Hoc Analysis of the OPTIMIZE Study Supporting XPHOZAH® (tenapanor) at the National Kidney Foundation Spring Clinical Meetings - The Manila Times
First-in-Class Kidney Disease Drug XPHOZAH Reveals Breakthrough Clinical Results - Stock Titan
Commit To Purchase Ardelyx At $4, Earn 20.5% Annualized Using Options - Nasdaq
Institutional owners may take dramatic actions as Ardelyx, Inc.'s (NASDAQ:ARDX) recent 6.4% drop adds to one-year losses - simplywall.st
How to Take Advantage of moves in (ARDX) - news.stocktradersdaily.com
Shareholders that lost money on Ardelyx, Inc.(ARDX) should contact Levi & Korsinsky about pending Class ActionARDX - ACCESS Newswire
Ardelyx Requests to Dismiss Class Action Filed by Investors - TradingView
DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Ardelyx - Marketscreener.com
ARDELYX INC- The GF Score's 5 Key Aspects of Analysis - GuruFocus.com
Trading (ARDX) With Integrated Risk Controls - news.stocktradersdaily.com
Ardelyx honors inaugural Derek Forfang award winners By Investing.com - Investing.com Australia
Ardelyx at Barclays Conference: Pipeline Expansion and Revenue Growth - Investing.com
Ardelyx at Barclays Conference: Pipeline Expansion and Revenue Growth By Investing.com - Investing.com UK
Ardelyx honors inaugural Derek Forfang award winners - Investing.com India
Ardelyx Announces the First Recipients of Derek Forfang Patient Advocate Award - The Manila Times
Five Champions of Kidney Disease Advocacy Receive Groundbreaking Ardelyx Recognition - StockTitan
Insider Buying: David Mott Acquires Shares of Ardelyx Inc (ARDX) - GuruFocus.com
Piper Sandler maintains $8 target on Ardelyx shares amid uncertainty By Investing.com - Investing.com South Africa
Piper Sandler maintains $8 target on Ardelyx shares amid uncertainty - Investing.com India
8,020 Shares in Ardelyx, Inc. (NASDAQ:ARDX) Bought by SBI Securities Co. Ltd. - Defense World
Ardelyx at Leerink Global Healthcare Conference: Navigating Challenges and Opportunities By Investing.com - Investing.com South Africa
Ardelyx at Leerink Global Healthcare Conference: Navigating Challenges and Opportunities - Investing.com India
Ardelyx Inc Stock (ARDX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):